<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03487393</url>
  </required_header>
  <id_info>
    <org_study_id>NRV_PI_01_15</org_study_id>
    <nct_id>NCT03487393</nct_id>
  </id_info>
  <brief_title>VitalFlow Healthy Volunteer Study</brief_title>
  <official_title>Determination of Threshold of Stimulation, Tolerability and Safety of Magnetic Nerve Stimulation In Healthy Subjects: an Exploratory Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nervive, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro Nacional de Investigacion en Imagenologia e Instrumentacion Medica (CI3M)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nervive, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Find the stimulation threshold of the facial nerve (ganglion Geniculate) associated with
      tolerability and safety in subjects Healthy humans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Magnetic stimulation of the facial nerve (geniculate ganglion) in humans can induce changes
      in cerebral blood flow safely, without generating adverse effects unknown to the technique.

      Our specific objectives:

        1. Perform tolerability and safety tests of magnetic stimulation on the facial nerve.

        2. Establish the optimal stimulation threshold associated with tolerability in order to
           apply it to the final design of the Magnetic Stimulation (MS) system.

        3. Measure whether the threshold found shows any increase in cerebral perfusion in the
           subject with respect to their baseline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2015</start_date>
  <completion_date type="Actual">January 8, 2016</completion_date>
  <primary_completion_date type="Actual">December 15, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in perfusion index of cerebral blood flow</measure>
    <time_frame>10 minutes post-stimulation</time_frame>
    <description>An algorithm to calculate the perfusion index using magnetic resonance images across the entire brain</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Normal Subject / Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Vitalflow treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subject's exposure will be through a ramp model of increments in magnetic stimulation power delivered to the facial nerves bilaterally. Increases in magnetic stimulation will be 10% for 10 seconds from 10% to 60%. Subsequent to this will be evaluated for 5 minutes in the power of tolerability of the subject (60% 70%, 80% or 90%).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>magnetic facial nerve stimulation</intervention_name>
    <description>Magnetic stimulation of facial nerve.</description>
    <arm_group_label>Vitalflow treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

          -  Normal audiometry chart (Evaluated at the time of your inclusion).

          -  Normal neurological examination at time of inclusion.

        Exclusion Criteria:

          -  Subjects with a diagnosis of epilepsy, seizures, facial nerve palsy, migraine or
             recurrent headaches, glaucoma or neuropathies.

          -  Subjects in breastfeeding or in pregnancy. (To be confirmed with test strip).

          -  Subjects with acute or acute chronic medical conditions.

          -  Age less than 20 years or greater than 40 years.

          -  Carotid surgery.

          -  Episodes of syncope.

          -  Known arteriosclerosis anywhere on the body

          -  Metal implants (cochlear implants, pacemakers, metal prostheses).

          -  Intracranial abnormalities observed by MRI or MRA (Evaluated at time of inclusion of
             the subject).

          -  Intraocular pressure&gt; 22mmHg (Evaluated at time of inclusion of the subject)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centro Nacional de Investigación en Imagenología e Instrumentación Medica</name>
      <address>
        <city>Mexico City</city>
        <state>Cdmx</state>
        <zip>09340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2018</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>facial nerve</keyword>
  <keyword>magnetic stimulation</keyword>
  <keyword>cerebral blood flow</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>available from investigators authors upon reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

